<p>Researcher from UC Davis Comprehensive Cancer Center recently presented new technology hope for potential treatment of cancer in the future. Technology involve development of antisense DNA by using Monoclonal antibody for acute lymphoblastic leukemia cells, which may offer best potential treatment for the disease.</p><p>The concern research recently appears in the journal Molecular Medicine. The study shows developed antisense DNA play an important role in reducing levels of a MXD3 type of protein molecule that help and support cancer cells to survive.</p><p>&amp;quot;We&#039;ve shown, for the first time, that anti-CD22 antibody-antisense conjugates are a potential therapeutic agent for ALL,&amp;quot; said Noriko Satake, associate professor in the Department of Pediatrics at UC Davis. &amp;quot;This could be a new type treatment that kills leukemia cells with few side effects.&amp;quot; The antisense DNA mainly inhibits MXD3 protein to an antibody binds with CD22 type of protein type receptor present in all types of cells and normal B Cells after binding of antibody to CD22 it prevents the production of MXD3.<br /><br /><a href="http://www.srlchem.com/" target="_blank" rel="noopener noreferrer"><img src="http://www.microbiozindia.com/images/ASX.png" alt="" /></a></p><p>&amp;quot;You really don&#039;t want to destroy hematopoietic stem cells because then you have to do a stem cell transplant, which is an extremely intensive therapy,&amp;quot; noted Satake. &amp;quot;Our novel conjugate is designed so that it does not harm hair, eyes, heart, kidneys or other types of cells.&amp;quot;</p><p><strong>Story source:</strong> UC Davis Comprehensive Cancer Center</p><p>For more information:</p><p>http://static.smallworldlabs.com/molmedcommunity/content/pdfstore/15_210_Satake.pdf</p>